ProCE Banner Activity

ACE-WM-001: Phase II Study of Acalabrutinib in Patients With Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

Slideset Download
Conference Coverage
Acalabrutinib monotherapy yielded a 93% ORR across cohorts with durable responses and a favorable safety profile.

Released: June 11, 2018

Expiration: June 10, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen